Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism
Abstract
Hypogonadism, characterized by low testosterone blood levels, affects 3%-5% of males worldwide. Oral testosterone undecanoate (TU) is emerging as a key route of administration due to its better ease of administration; however, it suffers from variable pharmacokinetics and pharmacodynamics. The variability is majorly attributed to intestinal glucuronidation of testosterone to its hydrophilic metabolite, testosterone glucuronide (TG), formed by the polymorphic uridine 5'-diphospho-glucuronosyltransferase 2B17 (UGT2B17). This study investigated the potential of curcumin, as a UGT2B17 inhibitor, to enhance TU bioavailability using a series of in vitro and in vivo studies. In human intestinal microsomes, curcumin inhibited UGT2B17 with an IC50 of 58 μM. In LS180 cells, a human intestinal cell line, curcumin reduced TG formation dose-dependently at 10, 25, and 100 μM, and also inhibited the formation of androstenedione at 100 μM. In primary human enterocytes, curcumin (100 μM) significantly reduced TG and androstenedione formation by ∼50%. A pilot crossover clinical study compared testosterone pharmacokinetics when TU was coadministered with curcumin in men with experimental hypogonadism. The plasma concentration-time area under the curve (AUC1-6h) and the peak plasma concentration (Cmax) for testosterone, representing the absorption phase, significantly increased by 50% and 80%, respectively, when TU was administered with curcumin. These findings suggest that curcumin, a UGT2B17…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Induced osteoblast differentiation by amide derivatives of stilbene: The possible osteogenic agents
- On model selections for repeated measurement data in clinical studies
- Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells
- Region-specific microRNA signatures in the human epididymis
- Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety
- In Vitro characterization of the endocrine disrupting effects of per- and poly-fluoroalkyl substances (PFASs) on the human androgen receptor
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.